
Novartis’ Zykadia smashes Phase III target for lung cancer
pharmafile | September 23, 2016 | News story | Medical Communications, Research and Development |Â Â Novartis, lung cancer, zykadiaÂ
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating its efficacy in treating patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.
Zykadia, an orally-administered selective inhibitor of anaplastic lymphoma kinase, showed a significant improvement in progression-free survival in previously untreated patients compared to standard chemotherapy.
Alessandro Riva, global head of Oncology Development and Medical Affairs at Novartis Oncology, explained: “Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib. We are pleased to see these topline results show promise in untreated patients with advanced disease, and look forward to sharing these data with regulatory authorities in the coming months.”
Zykadia has been approved in 55 countries and generated $24 million in Q2 sales.
Matt Fellows
Related Content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …






